Intrahepatic cholestasis after griseofulvin administration.
The occurrence of cholestatic jaundice in a patient receiving griseofulvin is described. The clinical manifestations, laboratory features, and pathological lesion of drug-induced hepatotoxicity are discussed. Complete recovery followed the discontinuation of drug administration. The potential hepatotoxicity of griseofulvin and the importance of close monitoring of liver function studies in patients receiving this drug are emphasized.
D001707:Biopsy, Needle; D002779:Cholestasis / Q000139:chemically induced* / Q000473:pathology; D006118:Griseofulvin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D014009:Onychomycosis / Q000188:drug therapy
D006118:Griseofulvin